The use and utility of toolkits in supporting cabotegravir plus rilpivirine long-acting implementation in the CARISEL (Cabotegravir And Rilpivirine Implementation Study in European Locations) study

被引：0
|
作者：
Trehan, Rekha [1 ]
Gutner, Cassidy [2 ]
Okoli, Chinyere [1 ]
Ghosn, Jade [3 ]
Vera, Francisco [4 ]
Florence, Eric [5 ]
Lutz, Thomas [6 ]
van der Valk, Marc [7 ,8 ]
Czarnogorski, Maggie [2 ]
机构：
[1] ViiV Healthcare, Brentford, England
[2] ViiV Healthcare, Durham, NC USA
[3] Univ Paris, Paris, France
[4] Hosp Gen Univ Santa Lucia, Murcia, Spain
[5] Inst Trop Geneeskunde, Antwerp, Belgium
[6] Infekt Res, Frankfurt, Germany
[7] Univ Amsterdam, Amsterdam, Netherlands
[8] Amsterdam Inst Infect & Immun, Amsterdam, Netherlands
来源：
HIV MEDICINE | 2023年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
P111
引用
收藏
页码：93 / 93
页数：1
相关论文
共 50 条
  • [1] Efficacy, safety and implementation outcomes of Cabotegravir plus Rilpivirine long-acting by country in the Cabotegravir and rilpivirine implementation study in European locations (CARISEL)
    Jonsson-Oldenbuettel, C.
    Ghosn, J.
    Sierra, J. Olalla
    van der Valk, M.
    Lutz, T.
    Belkhir, L.
    van Welzen, B. J.
    Hove, K.
    Ait-Khaled, M.
    DeMoor, R.
    Bontempo, G.
    Latham, C. L.
    Ngenzi, B.
    Okoli, C.
    Gutner, C. A.
    Iyer, S.
    Gill, M.
    Czarnogorski, M.
    D'Amico, R.
    van Wyk, J.
    HIV MEDICINE, 2023, 24 : 193 - 195
  • [2] Patient Participant Perspectives on Implementation of Long-Acting Cabotegravir and Rilpivirine: Results From the Cabotegravir and Rilpivirine Implementation Study in European Locations (CARISEL) Study
    Gutner, Cassidy A.
    van der Valk, Marc
    Portilla, Joaquin
    Jeanmaire, Eliette
    Belkhir, Leila
    Lutz, Thomas
    Demoor, Rebecca
    Trehan, Rekha
    Scherzer, Jenny
    Pascual-Bernaldez, Miguel
    Ait-Khaled, Mounir
    Hernandez, Beatriz
    de Ruiter, Annemiek
    Anand, Savita Bakhshi
    Low, Emma L.
    Hadi, Monica
    Barnes, Nicola
    Sevdalis, Nick
    Mohammed, Perry
    Czarnogorski, Maggie
    JOURNAL OF THE INTERNATIONAL ASSOCIATION OF PROVIDERS OF AIDS CARE, 2024, 23
  • [3] Implementation of long-acting cabotegravir and rilpivirine: primary results from the perspective of staff study participants in the Cabotegravir And Rilpivirine Implementation Study in European Locations
    Gutner, Cassidy A.
    Hocqueloux, Laurent
    Jonsson-Oldenbuettel, Celia
    Vandekerckhove, Linos
    van Welzen, Berend J.
    Slama, Laurence
    Crusells-Canales, Maria
    Sierra, Julian Olalla
    DeMoor, Rebecca
    Scherzer, Jenny
    Ait-Khaled, Mounir
    Bontempo, Gilda
    Gill, Martin
    Patel, Natasha
    D'Amico, Ronald
    Hove, Kai
    Baugh, Bryan
    Barnes, Nicola
    Hadi, Monica
    Low, Emma L.
    Anand, Savita Bakhshi
    Hamilton, Alison
    Garges, Harmony P.
    Czarnogorski, Maggie
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 (07)
  • [4] Implementation of cabotegravir and rilpivirine long-acting (CAB plus RPV LA): primary results from the CAB plus RPV Implementation Study in European Locations (CARISEL)
    Van Welzen, B.
    Vandekerckhove, L.
    Jonsson-Oldenbuettel, C.
    Hocqueloux, L.
    Ait-Khaled, M.
    Bontempo, G.
    DeMoor, R.
    Scherzer, J.
    D'Amico, R.
    Barnes, N.
    Hadi, M.
    Low, E.
    Anand, S.
    Czarnogorski, M.
    Gutner, C.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 71 - 72
  • [5] Perceptions of cabotegravir and rilpivirine long-acting (CAB plus RPV LA) from patients in the CAB plus RPV implementation study in European locations (CARISEL)
    Lutz, Thomas
    Jeanmaire, Eliette
    Portilla, Joaquin
    Scherzer, Jenny
    Trehan, Rekha
    Pascaul-Bernaldez, Miguel
    DeMoor, Rebecca
    Ait-Khaled, Mounir
    Hadi, Monica
    Anand, Savita Bakhshi
    Low, Emma L.
    Czarnogorski, Maggie
    Gutner, Cassidy A.
    Neumann, Jeanette
    HIV MEDICINE, 2023, 24 : 20 - 21
  • [6] Perceptions of cabotegravir and rilpivirine long-acting (CAB plus RPV LA) from patients in the CAB plus RPV Implementation Study in European Locations (CARISEL)
    Lutz, T.
    Jeanmaire, E.
    Portilla, J.
    Scherzer, J.
    Trehan, R.
    Pascual-Bernaldez, M.
    DeMoor, R.
    Ait-Khaled, M.
    Hadi, M.
    Anand, S.
    Low, E.
    Czarnogorski, M.
    Gutner, C.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 117 - 118
  • [7] Safety and Effectiveness From the Cabotegravir and Rilpivirine Implementation Study in European Locations Study: Phase 3b Hybrid Type III Implementation Study Integrating Cabotegravir plus Rilpivirine Long-Acting Into European Clinical Settings
    Jonsson-Oldenbuettel, Celia
    Ghosn, Jade
    van der Valk, Marc
    Florence, Eric
    Vera, Francisco
    De Wit, Stephane
    Rami, Agathe
    Bonnet, Fabrice
    Hocqueloux, Laurent
    Hove, Kai
    Ait-Khaled, Mounir
    DeMoor, Rebecca
    Bontempo, Gilda
    Latham, Christine L.
    Gutner, Cassidy A.
    Iyer, Supriya
    Gill, Martin
    Czarnogorski, Maggie
    D'Amico, Ronald
    van Wyk, Jean
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2024, 96 (05) : 472 - 480
  • [8] Perspectives on the acceptability, appropriateness, feasibility, barriers, and facilitators from patients receiving cabotegravir plus rilpivirine long-acting injectable treatment (CAB plus RPV LA): interim results from the Cabotegravir and Rilpivirine Implementation Study in European Locations (CARISEL)
    Hocqueloux, L.
    Gutner, C.
    DeMoor, R.
    Gill, M.
    Trehan, R.
    D'Amico, R.
    Tomkins, S.
    Schroeder, M.
    Bontempo, G.
    Ait-Khaled, M.
    Hadi, M.
    Anand, S. Bakhshi
    Low, E. L.
    Jeanmaire, E.
    Crusells Canales, M.
    Vandekerckhove, L.
    Bonnet, F.
    Olalla Sierra, J.
    Czarnogorski, M.
    HIV MEDICINE, 2021, 22 : 99 - 99
  • [9] Cabotegravir and Rilpivirine Implementation Study in European Locations (CARISEL): examining health care staff attitudes during a hybrid III implementation-effectiveness trial implementing cabotegravir plus rilpivirine long-acting injectable (CAB plus RPV LA) for people living with HIV (PLHIV)
    Gutner, C.
    Dakhia, S.
    Gill, M.
    Pascual-Bernaldez, M.
    Hernandez, B.
    Rami, A.
    Portilla, J.
    Lutz, T.
    van der Valk, M.
    Florence, E.
    Barnes, N.
    Cooper, O.
    Filipenko, D.
    Hamilton, A.
    Bosse, M.
    Czarnogorski, M.
    HIV MEDICINE, 2021, 22 : 114 - 115
  • [10] Overcoming barriers and achieving optimal implementation of cabotegravir and rilpivirine long-acting (CAB plus RPV LA): staff study participant (SSP) results from the CAB plus RPV Implementation Study in European Locations (CARISEL)
    Slama, L.
    Crusells-Canales, M.
    Olalla, J.
    DeMoor, R.
    Ait-Khaled, M.
    Dakhia, S.
    Van Mechelen, H.
    Hamilton, A.
    Hadi, M.
    Filipenko, D.
    Brown, F.
    Low, E.
    Gutner, C.
    Czarnogorski, M.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 111 - 112
12345